APR-246, also known as PRIMA-1MET, is primarily used in cancer research and therapy. It functions as a reactivator of mutant p53, a tumor suppressor protein that is often inactivated in various cancers. By restoring the normal function of p53, APR-246 helps induce apoptosis in cancer cells, making it a promising candidate for treating cancers with p53 mutations. It is being studied in clinical trials for its potential in treating hematologic malignancies, such as acute myeloid leukemia (AML), and solid tumors like ovarian and prostate cancer. Additionally, APR-246 is explored for its synergistic effects when combined with other chemotherapeutic agents, enhancing overall treatment efficacy. Its ability to target cancer cells while sparing normal cells makes it a valuable tool in precision medicine.